business
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Key takeaways
- According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, High Vista Strategies reduced its position in Maze Therapeutics by 70,503 shares during the first quarter.
- This was a sale, leaving Maze Therapeutics at 0.82% of reported AUM.
- NYSEMKT:DBC: $30.61 million (8.5% of AUM)
Jonathan Ponciano, The Motley Fool Mon, May 18, 2026 at 2:13 AM GMT+7 4 min read MAZE ABVX SYRE PRAX COGT On May 15, 2026, High Vista Strategies disclosed it sold 70,503 shares of Maze Therapeutics (NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing.
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, High Vista Strategies reduced its position in Maze Therapeutics by 70,503 shares during the first quarter. The estimated value of the shares sold was $3.11 million, based on the average closing price for the quarter. The fund ended the period with 99,850 shares, worth $2.98 million.
This was a sale, leaving Maze Therapeutics at 0.82% of reported AUM.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop